The company said that it expected its revenues to decline in 2017 as several of its products lose their exclusivity and
generic competitors enter the market.
Not exact matches
Often it turns out that the price increases by Valeant and Turing that have provoked the most criticism have been on drugs that are off - patent — meaning
generic competitors are free to
enter the market, typically bringing the price that most people pay for the drugs way down.
The Bureau characterized diverging views as follows: are these agreements a «lawful application of the exclusionary powers granted by a patent», OR do these agreements simply «pay potential
generic competitors not to
enter the marketplace, thereby lessening competition»?